Top 10 AI Picks with Upcoming Opportunity Windows

1. CLSD: Clearside Biomedical Poised For Breakout With Pioneering Eye Treatment Trials (Score: 65)
   Start: 2025-06-01 | End: 2025-09-30 | Close: $0.81 | Target: $3.00
2. RGLS: Regulus Therapeutics Set For Breakout Amid Promising ADPKD Clinical Trials (Score: 65)
   Start: 2025-07-10 | End: 2025-09-30 | Close: $8.16 | Target: $12.00
3. ABEO: Abeona Therapeutics Nears Transformative FDA Decision (Score: 65)
   Start: 2025-07-10 | End: 2025-08-10 | Close: $5.89 | Target: $10.00
4. XBIT: XBiotech Poised For Breakout With Upcoming Phase II Trial Results (Score: 65)
   Start: 2025-07-10 | End: 2026-03-20 | Close: $3.18 | Target: $6.50
5. QURE: UniQure Set For Breakout Amid Promising Gene Therapy Advances (Score: 70)
   Start: 2025-07-10 | End: 2025-08-30 | Close: $14.42 | Target: $35.00
6. AMRN: Amarin Poised For Breakout With Key Approvals And Global Expansion (Score: 65)
   Start: 2025-07-10 | End: 2025-08-10 | Close: $16.73 | Target: $18.50
7. PULM: Strategic Merger And Clinical Advances Propel Pulmatrix (Score: 65)
   Start: 2025-07-10 | End: 2025-08-15 | Close: $6.53 | Target: $8.50
8. SAGE: Sage Therapeutics Set For Breakout On Upcoming Trial Results (Score: 65)
   Start: 2025-07-15 | End: 2025-08-15 | Close: $9.20 | Target: $12.50
9. AKBA: Akebia Therapeutics Set For Breakout Amid Strong Clinical Outcomes (Score: 65)
   Start: 2025-07-15 | End: 2025-08-15 | Close: $3.62 | Target: $6.50
10. VSTM: Verastem Poised For Breakout With Imminent FDA Approval (Score: 70)
    Start: 2025-07-20 | End: 2025-08-15 | Close: $4.80 | Target: $6.50